henhaobio
Sign in

bioRxivMicrobiologyPreprint

Single phage proteins sequester TIR- and cGAS-generated signaling molecules

D. Li, Y. Xiao, W. Xiong, I. Fedorova, Y. Wang, X. Liu, E. Huiting, J. Ren, Z. Gao, X. Zhao, X. Cao, Y. Zhang, J. Bondy-Denomy, Y. Feng

PDFDOI

Abstract

Prokaryotic anti-phage immune systems use TIR (toll/interleukin-1 receptor) and cGAS (cyclic GMP-AMP synthase) enzymes to produce 1-3/1-2 glycocyclic ADPR (gcADPR) and cyclid di-/tri-nucleotides (CDNs and CTNs) signaling molecules that limit phage replication, respectively 1-3. However, how phages neutralize these common systems is largely unknown. Here, we show that Thoeris anti-defense proteins Tad1 4 and Tad2 5 both have anti-CBASS activity by simultaneously sequestering CBASS cyclic oligonucleotides. Strikingly, apart from binding Thoeris signals 1-3 and 1-2 gcADPR, Tad1 also binds numerous CBASS CDNs/CTNs with high affinity, inhibiting CBASS systems using these molecules in vivo and in vitro. The hexameric Tad1 has six binding sites for CDNs or gcADPR, which are independent from two high affinity binding sites for CTNs. Tad2 also sequesters various CDNs in addition to gcADPR molecules, inhibiting CBASS systems using these CDNs. However, the binding pockets for CDNs and gcADPR are different in Tad2, whereby a tetramer can bind two CDNs and two gcADPR molecules simultaneously. Taken together, Tad1 and Tad2 are both two-pronged inhibitors that, alongside anti-CBASS protein 2, establish a paradigm of phage proteins that flexibly sequester a remarkable breadth of cyclic nucleotides involved in TIR- and cGAS-based anti-phage immunity.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISFedorova '26Cao '23Leavitt '22Roberts '25Huiting '22Hobbs '26
82% semantic matchMicrobiology
Iana Fedorova, Yourun Yue, Zirui Gao+9 more·bioRxiv·Jun 5, 2026· 1 citations